Why Smith & Nephew plc Is Attracting Interest From Stryker Corporation

Royston Wild explains why Smith & Nephew plc (LON: SN) could prove a shrewd purchase for Stryker Corporation (NYSE: SYK).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Shares in medical equipment manufacturer Smith & Nephew (LSE: SN) have exploded in pre-Christmas trading as speculation over a potential takeover by American group Stryker reaches fever pitch.

The London-based company is currently up around 8% at the time of writing, with shareholders cheering rumours that Smith & Nephew could be the latest healthcare specialist to be snapped up as M&A activity in the sector heats up. Here, I explain why the British company is attracting admiring gazes from across the Atlantic.

Imminent bid on the cards?

According to Bloomberg, surgical implant provider Stryker is readying a bid to acquire Smith & Nephew, a move that could be launched in the coming weeks. The US business commented in May that it was not about to launch a takeover offer for Smith & Nephew, preventing it from readying an attempt until late November at the earliest in line with stock market rules.

The report cited one source who explained that Smith & Nephew could command a premium of up to 30% of its share price. And unlike Pfizer’s attempted acquisition of AstraZeneca earlier this year, Stryker’s rumoured bid is apparently not being fuelled by controversial tax inversion, illustrating the underlying value of the British firm.

Earnings on course to ignite

Indeed, Europe’s largest manufacturer of artificial limbs has a stellar history of generating year-on-year earnings growth, and City analysts expect the business to punch growth to the tune of 4% in 2014, a figure which accelerates to 12% in 2015.

In response to escalating pressure from government and private health plans concerning the cost of its artificial body parts, this summer Smith & Nephew launched its Syncera initiative in the US, a strategy which could cut costs by half as part of a slimmed-down service. It is estimated that the scheme addresses between 5% and 10% of the market, and could drive Smith & Nephew’s current US market share — which currently stands at around 11% — through the roof.

On top of this, the business is also engaged in extensive work behind the scenes to bulk up the bottom line. From engaging in a vast $120m cost-stripping exercise, to rolling out IT systems which assist decision making by measuring profits according to product and country, Smith & Nephew is gearing up to build a much more intelligent earnings-generating machine.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Dividend Shares

I asked ChatGPT to build the perfect passive income portfolio and here’s the result

Jon Smith turns to the world of AI to try and find out whether ChatGPT could build an investor a…

Read more »

Investing Articles

£20,000 to invest? Here’s how the FTSE 100 could deliver a £2,040 passive income

Here are two ways that investors with a lump sum to spend could target a large passive income with FTSE…

Read more »

Runner standing at the starting point with 2025 year for starting in new year 2025 to achieve business planing and success concept.
Investing Articles

Here’s how someone could start investing in 2025 with just £1,000

Planning to start investing in 2025? This writer highlights two very different stocks that might be worth considering for a…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

I asked ChatGPT which UK stocks Warren Buffett might look to buy. It suggested these 5 names

ChatGPT has some ideas about FTSE 100 stocks Warren Buffett might have been buying. But Stephen Wright thinks a closer…

Read more »

Investing Articles

Up 14% today! Here’s one growth stock that Elon Musk likes

A UK growth stock has signed another contract with SpaceX. But does this mean it deserves a place in my…

Read more »

Investing Articles

I asked ChatGPT if the FTSE 100 would hit 10,000 this year. It’s feeling bullish!

The FTSE 100's flying and Harvey Jones is feeling bullish. His obvious next step was to ask a chatbot where…

Read more »

Investing Articles

Near 52-week lows, are these FTSE 100 stocks now unmissable bargains?

Two FTSE 100 titans just can't stop falling in value. Paul Summers looks at whether investors should see this as…

Read more »

Investing Articles

Bill Ackman just loaded up on this top stock for his FTSE 100-listed fund

The well-known hedge fund manager has announced a massive holding in this tech stock for his FTSE 100-listed investment trust.

Read more »